{"nctId":"NCT02624518","briefTitle":"68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer","startDateStruct":{"date":"2015-11-16","type":"ACTUAL"},"conditions":["Prostate Adenocarcinoma"],"count":122,"armGroups":[{"label":"Diagnostic (68Ga-RM2 PET/MRI)","type":"EXPERIMENTAL","interventionNames":["Drug: 68Ga-RM2","Procedure: Magnetic Resonance Imaging","Procedure: Positron Emission Tomography"]}],"interventions":[{"name":"68Ga-RM2","otherNames":["Gallium (68Ga)-labeled gastrin-releasing peptide receptor (GRPr) antagonist","68Ga-DOTA RM2","BAY 86-7548","68Ga-Bombesin","DOT-bombesin"]},{"name":"Magnetic Resonance Imaging","otherNames":["Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MRI"]},{"name":"Positron Emission Tomography","otherNames":["PET"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Biopsy proven prostate adenocarcinoma\n* Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy\n\n  * Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation\n\n    * PSA greater than 0.2 ng/mL measured 6-13 weeks after RP\n    * Confirmatory persistent PSA greater than 0.2 ng/mL\n  * Post-radiation therapy - American Society for Therapeutic Radiology and Oncology (ASTRO)-Phoenix consensus definition\n\n    * Nadir plus (+) greater than or equal to 2 ng/mL rise in PSA\n* No evidence of metastatic disease on conventional imaging, including a negative bone scan for skeletal metastasis and negative contrast-enhanced CT\n* Able to provide written consent\n* Karnofsky performance status of \\>= 50 (or Eastern Cooperative Oncology Group \\[ECOG\\]/World Health Organization \\[WHO\\] equivalent)\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Inability to lie still for the entire imaging time\n* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)\n* Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance\n* Metallic implants","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI","description":"Diagnostic performance of 68Ga-RM2 as a contrast imaging label will be assessed by magnetic resonance imaging (MRI) alone, or as a combined scan with positron emission tomography (PET, collectively PET/MRI). The outcome is reported as the number of tumor lesions detected with MRI alone, or with the combination PET/MRI scan, a number without dispersion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null}]}]}]},{"type":"PRIMARY","title":"Sensitivity of MRI Alone vs PET/MRI","description":"Sensitivity is the ability of a test to correctly identify patients who have the prostate cancer, ie, how well 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI correctly detects patients who truly have prostate cancer. Sensitivity is defined as \\[TP/(TP+FN)\\], where TP=true-positive, and FN=false-negative. The outcome is a percentage number with 95% confidence interval (95% CI). A higher % value means a greater probability that an imaging target identified as cancerous is confirmed by histology to be cancerous, and a lower % means reduced confidence in that result.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Specificity of MR Alone vs PET/MRI","description":"Specificity is the ability of a test to correctly identify patients who do not have the prostate cancer, ie, how well 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI correctly detects patients who do not have prostate cancer (does not falsely return a positive result). Specificity is defined as \\[TN/(TN+FP)\\], where TN=true-negative, and FP=false-positive. The outcome is a percentage number with 95% confidence interval (95% CI). A higher % value means a greater probability that an imaging target identified as non-cancerous is confirmed by histology to be non-cancerous, and a lower % means reduced confidence in that result.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":122},"commonTop":[]}}}